| Product Code | DAT14478 |
|---|---|
| Publication Date | March 2009 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 26 |
Datamonitor's CSL - SWOT Analysis company profile is the essential source for top-level company data and information. CSL - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
CSL is a specialty biopharmaceutical group engaged in developing, manufacturing and marketing of vaccines and plasma protein biotherapies. The group operates globally through its human health businesses that include the operations of CSL Behring, CSL Bioplasma and CSL Biotherapies, as well as new product development activities. CSL is headquartered in Victoria, Australia and employed about 9,276 people as of June 2008. The group recorded revenues of A$3,794 million (approximately $3,401.2 million*) during the financial year (FY) ended June 2008, an increase of 14.6% over FY2007. The increase in revenues was primarily attributable to the strong demand across product portfolios of CSL Behring and CSL Biotherapies coupled with new product launches and approvals during FY2008. The operating profit of the group was A$993 million (approximately $890.2 million*) during FY2008, an increase of 21.7% over FY2007. The net profit was A$702 million (approximately $629.3 million*) in FY2008, an increase of 30.2% over FY2007. *Average Currency Conversion Rate: A$1 = $0.89646 for the financial year ended June 2008.
PDF:Delivered by email usually within 4 to 8 UK business hours.
© 2010 | Report Buyer is a trading name for Piribo Ltd. Registered in England and Wales No. 05051530 | VAT Reg No. GB 839 4556 85